MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
16.20
-0.60
-3.54%
Opening 11:53 09/29 EDT
OPEN
16.67
PREV CLOSE
16.79
HIGH
16.71
LOW
15.97
VOLUME
394.60K
TURNOVER
4.36M
52 WEEK HIGH
28.06
52 WEEK LOW
12.24
MARKET CAP
2.62B
P/E (TTM)
-12.7933
1D
5D
1M
3M
1Y
5Y
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Benzinga · 09/12 22:29
FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Acadia Pharmaceuticals (NASDAQ:ACAD) on Monday <a hre...
Seekingalpha · 09/12 17:50
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.
Benzinga · 09/12 13:15
Acadia Pharmaceuticals Says US FDA Accepts NDA, Grants Priority Review to Trofinetide for Rett Syndrome
Acadia Pharmaceuticals Says US FDA Accepts NDA, Grants Priority Review to Trofinetide for Rett Syndrome
MT Newswires · 09/12 09:03
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/07 15:30
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, September 01, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Business Wire · 09/01 13:03
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Benzinga · 08/31 18:52
Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade
The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Zacks · 08/30 13:55
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The Company has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The Company also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.